Is GRCE or GTBP more undervalued in 2026?

CirclFi compares Grace Therapeutics, Inc. (GRCE) and GT Biopharma, Inc. (GTBP) using 13 institutional-grade valuation models. GRCE has a Quality of Company score of 4.6/10 while GTBP scores 3.5/10.

Which is a better buy — GRCE or GTBP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GRCE and GTBP valuations compare?

GRCE at $2.43 and GTBP at $0.45 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GRCE vs GTBP Valuation Comparison 2026 — Intrinsic Value Analysis

GRCE

Biotechnology

Grace Therapeutics, Inc.

Quality

4.6

out of 10

Value Trap

WARN

Price

$2.43

Last close

Models

7/13

Active

GTBP

Biotechnology

GT Biopharma, Inc.

Quality

3.5

out of 10

Value Trap

SAFE

Price

$0.45

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	GRCE Fair Value	GRCE Upside	GTBP Fair Value	GTBP Upside
Bayesian DCF	Intrinsic	$1.31	-46.0%	$0.25	-42.8%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	—	—	$0.06	-83.6%
ML-RIV	Intrinsic	$4.05	+66.7%	$0.04	-89.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GRCE vs GTBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GRCE vs GTBP — Which Stock Is More Undervalued?

GRCE scores higher with a 4.6/10 quality rating vs GTBP's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Grace Therapeutics, Inc. (GRCE) and GT Biopharma, Inc. (GTBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GRCE currently trades at $2.43 with a QOC of 4.6/10, while GTBP trades at $0.45 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).